What Imojev Treats: Main Uses and Benefits

Imojev is commonly used for the active prevention, or prophylaxis, of the serious neurological disease caused by the Japanese encephalitis virus (JEV). The primary therapeutic benefit is establishing a level of protection intended to assist in averting the development of acute brain inflammation (encephalitis) and meningoencephalitis, conditions generally associated with significant morbidity. The vaccine is relevant for managing the overall risk associated with JEV exposure.

This prophylactic use may assist in reducing the risk of severe outcomes, which include potential long-term neurological sequelae such as persistent cognitive impairment, movement disorders, and chronic seizure disorders. The vaccine is indicated for use in individuals, including travelers and residents of JEV endemic areas in Asia and the Western Pacific, or those with related occupational exposure. The support provided by this immunization is relevant for easing the overall systemic burden posed by JEV exposure in rural or agricultural settings.

This active immunization is relevant for individuals entering or residing in JEV transmission areas, contributing to protection against the disease's most severe symptomatic manifestations.

Quick Fact: Supportive Management of Neurological Risk

The eligibility for the Imojev vaccine is strictly defined by regulatory authorities based on age, immune status, and reproductive status. Official prescribing information states that the vaccine is allowed for use in populations 9 months of age and over.

Imojev is formally contraindicated in several specific populations. Absolute contraindications include individuals with a history of anaphylaxis to any vaccine component and persons who are pregnant or breastfeeding. Due to its nature as a live attenuated viral vaccine, it is also contraindicated in individuals with congenital or acquired immune deficiency, including those with symptomatic HIV infection or those receiving high-dose immunosuppressive therapies (e.g., systemic corticosteroids for 14 days).

Use is not established or not recommended for infants younger than 9 months. Additional restrictions require that vaccination be postponed in the event of an acute febrile illness and delayed for 6 weeks (preferably 3 months) following the receipt of immunoglobulins or blood products. Women must also avoid conception for 28 days after receiving the vaccine.

Imojev Interactions with other medicines and products

Imojev, as a live attenuated vaccine, has an interaction profile centered on the potential for pharmacodynamic interference with the body's immune response. The official regulatory data does not document any classical pharmacokinetic interactions, such as those related to CYP enzymes, drug transporters, food, or herbal products.

Interactions Governing Administration Timing

The most significant restrictions involve timing and separation rules:

• Immunosuppressive Agents: Vaccination is advised only after immune function has recovered, typically requiring a minimum wait of one month or more following the interruption of therapy (e.g., high-dose systemic corticosteroids).
• Immunoglobulins: To prevent neutralization of the vaccine virus, Imojev must not be given within six weeks, and preferably not within three months, following the injection of immunoglobulins or certain blood products.
• Other Live Parenteral Vaccines: Imojev may be administered at the same time as other specific live vaccines (e.g., Yellow Fever, MMR). If the vaccines are not given simultaneously, a minimum interval of at least four weeks (ge 28 days) is required between administrations. Co-administration of any vaccine necessitates the use of separate syringes and separate injection sites.

Imojev functions through the introduction of a live, attenuated strain of the Japanese Encephalitis (JE) virus. The attenuated viral particles replicate transiently within host cells, initiating a process that stimulates both the humoral and cellular arms of the immune system. This interaction type involves the biological target of the JE virus envelope protein (E), which is recognized by antigen-presenting cells. The subsequent mechanistic cascade leads to the activation and differentiation of B lymphocytes, resulting in the production of virus-specific neutralizing antibodies. Concurrently, T lymphocytes are activated and induced to become JE-specific effector and memory T cells. This combined pathway modulation establishes immunological memory through the persistence of memory B and T cells. This system-level physiological consequence enables a rapid and targeted response to limit JE viral replication and dissemination upon future exposure.

How to Use Imojev: Administration Guidelines

Imojev is a vaccine with specific parameters for use and administration. The following details describe the procedure for receiving the vaccine.

Administration Details

Dosing Schedule

Imojev is indicated for use in individuals 9 months of age and older. The primary immunization schedule consists of a single 0.5 mL injection.

• Adults (18 years and over): No booster dose is typically required for up to five years after the first vaccination.
• Children (9 months to under 18 years): The schedule includes one booster dose approximately one year after the primary dose if long-term protection is required.

These parameters define the procedural steps, including mandatory reconstitution, the injection volume, and the age-dependent injection site, characterizing the application of the medicine.

Research evidence / Overview of studies for Imojev

The clinical evaluation of Imojev was studied in a range of clinical research, including randomized controlled trials (RCTs) and long-term follow-up studies. Research mainly focused on immunogenicity, which measures the body's protective immune response, rather than direct disease case prevention. This approach relies on an established scientific measure called the immunologic correlate of protection—a specific level of neutralizing antibodies that is accepted as providing protective immunity against the Japanese encephalitis virus.

Evidence for Primary Immunization in Adults and Children

Research has explored the initial pattern of immunogenicity measured after a single-dose regimen of Imojev in both adult and pediatric populations.

Short-term RCTs were conducted in healthy adults (aged ge 18 years) who were not previously exposed to the JE virus. These studies monitored the rapid rise in protective antibody levels shortly after the dose was given. Studies reported measurements indicating that approximately 93% of adult participants achieved the seroprotection threshold within 14 days, and this figure was reported as approximately 99% after 30 days.

Similar Phase II and III trials were conducted in children and toddlers (aged 9 months and over). Studies monitored the time it took for the pediatric immune system to reach the established level of seroprotection. Research reports indicate that more than 95% of toddlers who received a single dose measured protective antibody levels 28 days following the vaccination.

Durability and Long-Term Persistence of Response

Research has explored the duration of measured antibody persistence after the primary single dose through long-term follow-up studies of the original clinical trial cohorts. These studies monitored the decay of antibody levels over many years.

In adult cohorts, data show patterns related to the maintenance of seroprotection. One randomized trial follow-up reported that protective antibody levels were observed in approximately 87% of adults who were seroprotected at the 6-month mark, at the 5-year (60-month) interval. Furthermore, cross-sectional observational studies have described seropositivity measurements exceeding 90% in some adults up to 10 years post-vaccination.

Data for long-term outcomes in toddlers and children show a different pattern. Estimates based on persistence models and follow-up data show patterns related to a potentially lower persistence of the measured seroprotection threshold in children over time compared to adults. In some trials, approximately 59% to 67% of toddlers who were initially seroprotected were estimated to still have these protective levels 5 years after the single primary dose.

Key Scientific Limitations and Research Gaps

The evidence highlights what is known—and what is still uncertain—about this vaccine. The regulatory authorization for Imojev is based on its ability to stimulate protective antibody levels (the immunologic correlate), and not on large-scale trials demonstrating prevention of actual disease cases. This reflects the typical research design in vaccine evaluation.

Furthermore, long-term effects are not fully established, particularly for duration of protection beyond 5 years, where limited information is available. In certain groups, such as older adults, data for subgroups remain insufficient. The results apply only to the populations studied and do not determine whether an individual will respond similarly. Finally, evidence suggests that the decline in antibody levels over time may vary significantly between children and adults, an area where research is ongoing.

Key Studies & References

1. Safety and immunogenicity of a live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®) in children
2. Immunogenicity and safety of currently available Japanese encephalitis vaccines: A systematic review
3. AusPAR Attachment 2: Extract from the Clinical Evaluation Report for Japanese Encephalitis Vaccine (live, attenuated) (Imojev)

Common questions about Imojev (FAQ)

Q: What is Imojev used to prevent?

Imojev is a vaccine that is used to prevent the disease Japanese encephalitis (JE). Regulatory documents indicate it is designed to stimulate the body's immune system to protect against the JE virus. This protection is intended for people traveling to or living in areas where JE is present.

Q: Does Imojev contain the live or inactive virus?

Imojev is a live attenuated vaccine. This means it contains a weakened (attenuated) form of the virus that has been modified so it cannot cause the disease. According to official product information, this weakened virus helps the immune system build protection.

Q: Is Imojev safe for use in children?

Official product information states that Imojev is indicated for use in individuals starting from 9 months of age who live in or are traveling to areas where Japanese encephalitis is endemic. For individuals in this age group, official product information describes a specific dosing schedule. However, a healthcare professional must determine the appropriate use and schedule based on local guidelines.

Q: How long does the protection from Imojev last?

Studies and official information indicate that a single dose of Imojev provides protection against Japanese encephalitis for at least 5 years in people who have not been vaccinated before. The official product information addresses the need for continued protection after 5 years, suggesting further vaccination may be considered based on risk and official guidelines.

Q: Can I receive Imojev with other vaccines?

According to the official product information, Imojev may be given at the same time as, or at any interval before or after, certain other vaccines, such as those for yellow fever, measles, mumps, and rubella. If it is given at the same time as other injectable vaccines, a different injection site should be used for each vaccine. Official guidance indicates that a healthcare professional should be consulted to determine the appropriate timing and administration if combining Imojev with other vaccines.

Storage Conditions

Imojev (lyophilized powder and diluent) must be stored in a refrigerator at a temperature between 2 C and 8 C as documented in official labeling. It is mandatory that the vaccine is not frozen.

The product must be kept in the original outer carton at all times to ensure protection from light. To meet child-safety requirements, the vaccine must be stored out of the sight and reach of children.

Stability and Handling

After reconstitution, the suspension should be used promptly. The reconstituted product must be discarded if it is not used within six hours of opening the vial.

Disposal Instructions

Unused or expired Imojev and its waste materials must not be disposed of via household waste or flushed into wastewater. Disposal must be conducted according to specific local regulatory requirements for pharmaceutical waste.